Should I buy or sell Janux Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Janux Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" JANX shares. View JANX analyst ratings or view top-rated stocks .

What is Janux Therapeutics' stock price target for 2024?

7 Wall Street research analysts have issued twelve-month price targets for Janux Therapeutics' stock. Their JANX share price targets range from $35.00 to $100.00. On average, they expect the company's stock price to reach $61.33 in the next year. This suggests a possible upside of 25.6% from the stock's current price. View analysts price targets for JANX or view top-rated stocks among Wall Street analysts .

How have JANX shares performed in 2024?

Janux Therapeutics' stock was trading at $10.73 at the beginning of 2024. Since then, JANX stock has increased by 355.3% and is now trading at $48.85. View the best growth stocks for 2024 here .

Are investors shorting Janux Therapeutics?

Janux Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 3,750,000 shares, an increase of 20.6% from the March 15th total of 3,110,000 shares. Based on an average daily volume of 711,600 shares, the short-interest ratio is presently 5.3 days. Approximately 11.6% of the company's shares are sold short. View Janux Therapeutics' Short Interest .

When is Janux Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our JANX earnings forecast .

How were Janux Therapeutics' earnings last quarter?

Janux Therapeutics, Inc. (NASDAQ:JANX) announced its earnings results on Friday, March, 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.12. The business had revenue of $2.46 million for the quarter, compared to analyst estimates of $0.98 million. Janux Therapeutics had a negative trailing twelve-month return on equity of 17.88% and a negative net margin of 721.18%.

What ETFs hold Janux Therapeutics' stock?

ETFs with the largest weight of Janux Therapeutics (NASDAQ:JANX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) . Fidelity Disruptive Medicine ETF (FMED) .

When did Janux Therapeutics IPO?

Janux Therapeutics (JANX) raised $152 million in an initial public offering on Friday, June 11th 2021. The company issued 9,500,000 shares at $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager.

Who are Janux Therapeutics' major shareholders?

Janux Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Corp Bregua, Orbimed Advisors Llc, Ra Capital Management, LP and Ventures Xi LP Avalon. View institutional ownership trends .

How do I buy shares of Janux Therapeutics?

Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:JANX

Janux Therapeutics (JANX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free JANX Stock Alerts

$48.85

+0.89 (+1.86%)

(As of 04/18/2024 ET)

Compare

Today's Range: $47.32
▼
$49.00
50-Day Range: $7.93
▼
$52.65
52-Week Range: $5.65
▼
$58.69

Volume: 396,700 shs
Average Volume: 736,989 shs
Market Capitalization: $2.52 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $61.33

Get Janux Therapeutics alerts:

Janux Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 25.6% Upside
$61.33 Price Target
Short Interest: Bearish
11.58% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.52
Based on 13 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.41) to ($1.64) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.59 out of 5 stars

Medical Sector

439th out of 918 stocks

Biotechnology Industry

8th out of 33 stocks

4.5

Analyst's Opinion

Consensus Rating
Janux Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Janux Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
11.58% of the float of Janux Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Janux Therapeutics has a short interest ratio ("days to cover") of 5.3.
Change versus previous month
Short interest in Janux Therapeutics has recently increased by 20.58%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Janux Therapeutics does not currently pay a dividend.
Dividend Growth
Janux Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for JANX.

2.0

News and Social Media Coverage

News Sentiment
Janux Therapeutics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 13 news articles for Janux Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 35 people have searched for JANX on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
MarketBeat Follows
Only 9 people have added Janux Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -10% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Janux Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
35.40% of the stock of Janux Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
75.39% of the stock of Janux Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Janux Therapeutics are expected to decrease in the coming year, from ($1.41) to ($1.64) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Janux Therapeutics is -36.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Janux Therapeutics is -36.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Janux Therapeutics has a P/B Ratio of 6.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Janux Therapeutics Stock (NASDAQ:JANX)

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

JANX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

JANX Stock News Headlines

April 17, 2024 | investorplace.com

Take the Money and Run: 3 Overbought Stocks to Sell ASAP

April 17, 2024 | nasdaq.com

Validea Detailed Fundamental Analysis - JANX

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 17, 2024 | americanbankingnews.com

Janux Therapeutics (NASDAQ:JANX) Now Covered by Analysts at Jonestrading

April 16, 2024 | msn.com

JonesTrading Initiates Coverage of Janux Therapeutics (JANX) with Buy Recommendation

April 16, 2024 | msn.com

Janux a new buy at Jones on lead assets for solid tumors

April 16, 2024 | investorplace.com

These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?

April 16, 2024 | benzinga.com

A Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 Analysts

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 15, 2024 | americanbankingnews.com

Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Recommendation of "Buy" by Brokerages

April 13, 2024 | americanbankingnews.com

Janux Therapeutics (NASDAQ:JANX) Shares Gap Up to $44.62

April 12, 2024 | fool.com

Why Janux Therapeutics Stock Is Crushing It This Week

April 11, 2024 | theglobeandmail.com

Stocks See Continued Pressure as Bond Yields Climb

April 11, 2024 | benzinga.com

Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday?

April 11, 2024 | finance.yahoo.com

Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options

April 11, 2024 | investors.com

Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options

April 10, 2024 | fool.com

Why Janux Therapeutics Stock Soared as the Market Sagged Today

April 10, 2024 | msn.com

Janux Therapeutics surges amid report of takeover interest

April 5, 2024 | morningstar.com

Janux Therapeutics Inc Ordinary Shares JANX

April 5, 2024 | nasdaq.com

Commit To Purchase Janux Therapeutics At $25, Earn 26.5% Annualized Using Options

March 20, 2024 | msn.com

Cantor starts Janux at overweight, cites TCE leadership position

March 20, 2024 | markets.businessinsider.com

Forecasting The Future: 4 Analyst Projections For Janux Therapeutics

March 20, 2024 | finance.yahoo.com

Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst

March 20, 2024 | benzinga.com

Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)

March 15, 2024 | investorplace.com

JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q4 2023

March 15, 2024 | fool.com

2 Stocks That Have More Than Tripled This Year: Are They Buys?

March 14, 2024 | markets.businessinsider.com

Stranahan Recommends Buy on Janux Therapeutics with Increased Price Objective Amid Promising Drug Advances

See More Headlines

Receive JANX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/08/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:JANX
CUSIP: N/A
CIK: 1817713
Web: www.januxrx.com
Phone: 858-751-4493
Fax: N/A
Employees: 64
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $61.33
High Stock Price Target: $100.00
Low Stock Price Target: $35.00
Potential Upside/Downside: +25.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-58,290,000.00
Net Margins: -721.18%
Pretax Margin: -721.18%
Return on Equity: -17.88%
Return on Assets: -15.95%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 26.80
Quick Ratio: 26.80

Sales & Book Value

Annual Sales: $8.08 million
Price / Sales: 312.21
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.46 per share
Price / Book: 6.55

Miscellaneous

Outstanding Shares: 51,660,000
Free Float: 33,372,000
Market Cap: $2.52 billion
Optionable: Optionable
Beta: 4.18

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. David Alan Campbell Ph.D. (Age 64)
President, CEO & Director
Comp: $852.5k
Mr. Byron Robinson J.D. (Age 59)
Ph.D., Chief Strategy Officer
Comp: $606.8k
Mr. Tighe M. Reardon C.F.A. (Age 47)
CPA, Acting Chief Financial Officer
Mr. Charles M. Winter (Age 55)
Chief Technical Officer
Dr. Tommy Diraimondo Ph.D.
Chief Scientific Officer
Mr. James Pennington
General Counsel
Ms. Brenda Van Vreeswyk
Head of Human Resources
Mr. Andy Hollman Meyer (Age 40)
Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

JANX Stock Analysis - Frequently Asked Questions

Should I buy or sell Janux Therapeutics stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Janux Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" JANX shares.
View JANX analyst ratings or view top-rated stocks.
What is Janux Therapeutics' stock price target for 2024?: 7 Wall Street research analysts have issued twelve-month price targets for Janux Therapeutics' stock. Their JANX share price targets range from $35.00 to $100.00. On average, they expect the company's stock price to reach $61.33 in the next year. This suggests a possible upside of 25.6% from the stock's current price.
View analysts price targets for JANX or view top-rated stocks among Wall Street analysts.
How have JANX shares performed in 2024?: Janux Therapeutics' stock was trading at $10.73 at the beginning of 2024. Since then, JANX stock has increased by 355.3% and is now trading at $48.85.
View the best growth stocks for 2024 here.
Are investors shorting Janux Therapeutics?: Janux Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 3,750,000 shares, an increase of 20.6% from the March 15th total of 3,110,000 shares. Based on an average daily volume of 711,600 shares, the short-interest ratio is presently 5.3 days. Approximately 11.6% of the company's shares are sold short.
View Janux Therapeutics' Short Interest.
When is Janux Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our JANX earnings forecast.
How were Janux Therapeutics' earnings last quarter?: Janux Therapeutics, Inc. (NASDAQ:JANX) announced its earnings results on Friday, March, 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.12. The business had revenue of $2.46 million for the quarter, compared to analyst estimates of $0.98 million. Janux Therapeutics had a negative trailing twelve-month return on equity of 17.88% and a negative net margin of 721.18%.

What ETFs hold Janux Therapeutics' stock?: ETFs with the largest weight of Janux Therapeutics (NASDAQ:JANX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Fidelity Disruptive Medicine ETF (FMED).
When did Janux Therapeutics IPO?: Janux Therapeutics (JANX) raised $152 million in an initial public offering on Friday, June 11th 2021. The company issued 9,500,000 shares at $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager.
Who are Janux Therapeutics' major shareholders?: Janux Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Corp Bregua, Orbimed Advisors Llc, Ra Capital Management, LP and Ventures Xi LP Avalon.
View institutional ownership trends.
How do I buy shares of Janux Therapeutics?: Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:JANX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial